Amneal Expands Leadership Team with Appointment of Senior Leaders in Quality and RegulatoryBusiness Wire • 10/31/22
Amneal Launches First Biosimilar with ALYMSYS® (bevacizumab-maly) in the United StatesBusiness Wire • 10/03/22
Amneal Appoints Gustavo Pesquin as Executive Vice President, Chief Commercial Officer – SpecialtyBusiness Wire • 09/06/22
Amneal Announces Submission of New Drug Application to the U.S. FDA for IPX203 for the Treatment of Parkinson's DiseaseBusiness Wire • 08/31/22
Amneal supports Congress' efforts to ensure essential medicines are Made in AmericaBusiness Wire • 08/22/22
Amneal Pharmaceuticals, Inc. (AMRX) Management Team on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/05/22
Amneal Releases 2021 Corporate Responsibility Report Highlighting Continued ESG Impact and IntegrationBusiness Wire • 06/07/22
Amneal Launches LYVISPAH® (baclofen) for Spasticity Related to Multiple Sclerosis and Other Spinal Cord DisordersBusiness Wire • 06/01/22
Amneal Achieves Third U.S. Biosimilar Approval with FYLNETRA™ (pegfilgrastim-pbbk)Business Wire • 05/27/22
Amneal Pharmaceuticals, Inc. (AMRX) Management Team on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/04/22
Amneal Achieves Second U.S. Biosimilars Approval with ALYMSYS® (bevacizumab-maly)Business Wire • 04/13/22
Amneal Pharmaceuticals: Generics And Biosimilars Play Has Strong Upside Potential Under New / Old ManagementSeeking Alpha • 03/30/22
Amneal to Present Results From the Pivotal Phase 3 RISE-PD Clinical Trial of IPX-203 at the 2022 American Academy of Neurology Annual MeetingBusiness Wire • 03/24/22
Amneal Awarded Sub-License to Manufacture and Commercialize Generic Version of Co-Packaged Nirmatrelvir and Ritonavir in 95 Low- and Middle-Income CountriesBusiness Wire • 03/17/22